Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...

AMSTERDAM – The European Medicines Agency (EMA) said on Jan 27 that it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media ...

Flu season has hit Poland hard, straining the country’s healthcare system. In response, Health Minister Izabela Leszczyna has requested assistance ...

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the ...

Belgian MEP Liesbet Sommen spoke with Euractiv about critical medicines shortages, EU Pharma Package progress, and SANT's evolving role.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...